CLIMARA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CLIMARA (CLIMARA).
Estradiol replacement therapy; binds to estrogen receptors, activating gene transcription leading to estrogenic effects in target tissues.
| Metabolism | Hepatic via CYP3A4; also undergoes conjugation (glucuronidation, sulfation). |
| Excretion | Renal: 70-80% as glucuronide and sulfate conjugates; biliary/fecal: 20-30%. |
| Half-life | Terminal elimination half-life is approximately 13–17 hours for estradiol via transdermal route, supporting once-weekly dosing. |
| Protein binding | Approximately 98% bound, primarily to sex hormone-binding globulin (SHBG) and albumin. |
| Volume of Distribution | Apparent Vd is about 1.5–2.0 L/kg, reflecting extensive distribution and tissue binding. |
| Bioavailability | Transdermal: Approximately 10–20% of the nominal dose delivered, bypassing first-pass metabolism; absolute bioavailability compared to oral is about 100% for absorbed dose. |
| Onset of Action | Transdermal: Therapeutic serum estradiol levels achieved within 4–8 hours; steady-state reached after 2–3 applications. |
| Duration of Action | 7 days per patch. Clinical effect maintained for 7 days with steady serum levels; patch replacement recommended every 7 days. |
Transdermal, 0.025-0.1 mg/day applied once weekly; start with lowest effective dose. Adjust based on clinical response.
| Dosage form | FILM, EXTENDED RELEASE |
| Renal impairment | No dose adjustment required for renal impairment; use with caution in severe impairment. |
| Liver impairment | Contraindicated in severe hepatic disease (Child-Pugh class C). In mild to moderate hepatic impairment, use with caution and monitor liver function; reduce dose if needed. |
| Pediatric use | Not recommended for use in pediatric patients; safety and efficacy not established. |
| Geriatric use | Initiate at lowest effective dose (0.025 mg/day); consider risk of thromboembolic events and malignancy; monitor closely. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for CLIMARA (CLIMARA).
| Breastfeeding | Estradiol is excreted in human milk. The milk-to-plasma (M/P) ratio for estradiol is approximately 0.1–0.2. Limited data suggest that transdermal estradiol results in lower milk concentrations compared to oral formulations. Use during breastfeeding is generally not recommended as it may decrease milk production and alter milk composition. Potential adverse effects in the nursing infant include jaundice, transient gynecomastia, and vaginal bleeding. If use is medically necessary, the lowest effective dose should be used and the infant monitored for estrogenic effects. |
| Teratogenic Risk | Pregnancy Category X. Use of estrogen-containing products, including Climara (estradiol transdermal system), is contraindicated during pregnancy. Estrogens are known to cause fetal harm when administered to pregnant women. First trimester exposure has been associated with an increased risk of congenital anomalies, particularly cardiovascular and central nervous system defects. Second and third trimester exposure may lead to urogenital abnormalities and other reproductive tract anomalies in female offspring, as well as potential long-term neurodevelopmental effects. The drug should not be used during pregnancy; if pregnancy occurs, therapy should be discontinued immediately. |
■ FDA Black Box Warning
Estrogens should not be used to prevent cardiovascular disease or dementia. Increased risk of endometrial cancer, stroke, deep vein thrombosis, pulmonary embolism, myocardial infarction, and breast cancer.
| Serious Effects |
Undiagnosed abnormal genital bleeding, known or suspected pregnancy, breast cancer (known, suspected, or history), estrogen-dependent neoplasia, active DVT/PE or history, active arterial thromboembolic disease, hypersensitivity to any ingredient, hepatic impairment or disease.
| Precautions | Increased risk of endometrial cancer (use progestin if uterus intact), cardiovascular disorders, thromboembolism, gallbladder disease, hypercalcemia, visual abnormalities, and hereditary angioedema. Should be used at the lowest effective dose for shortest duration. |
Loading safety data…
| Fetal Monitoring | In the rare event of accidental exposure during pregnancy, fetal monitoring is not specifically indicated for estrogen exposure. However, pregnancy should be confirmed negative before initiating therapy. Routine prenatal care with ultrasound to assess fetal anatomy is recommended if exposure occurs. No specific maternal monitoring beyond standard obstetric care is required. |
| Fertility Effects | Climara may suppress ovulation through negative feedback on gonadotropin secretion, potentially impairing fertility. When used as hormone replacement therapy, it is not indicated for contraception. Rebound ovulation may occur after discontinuation. In women of reproductive potential, effective non-hormonal contraception should be used during therapy. |